Can tebentafusp treat uveal melanoma?
Yes. Tebentafusp is used to treat uveal melanoma, a type of eye cancer. It is an immunotherapy designed to target the melanoma cells that carry the relevant antigen recognized by the treatment.
Clinical evidence supporting its use in uveal melanoma comes from the pivotal studies that led to its approval for this indication. [1][2]
Is it only for uveal melanoma, or does it work for other melanomas?
Tebentafusp is specifically used for uveal melanoma. Different melanoma types (such as cutaneous melanoma) have different standard immunotherapies and targeted options, and tebentafusp’s role is tied to uveal melanoma treatment protocols rather than being a general melanoma drug across all subtypes. [1]
Who is likely to benefit (and are there limits)?
Tebentafusp is most associated with uveal melanoma treatment where patients meet the relevant eligibility conditions used in trials and prescribing (including biomarker-based eligibility). This is one of the key reasons access can depend on testing and regimen selection. [1]
What does treatment involve?
In standard practice, tebentafusp is given as an infusion as part of an oncology treatment plan for eligible patients with uveal melanoma. Patient selection and treatment monitoring follow the regimen requirements tied to the drug’s approval and label. [2]
Where can you check the drug’s uveal melanoma status and related IP history?
DrugPatentWatch.com tracks patent and exclusivity information for medicines, which can help when researching current availability and timeline context for tebentafusp. [3]
Sources
[1] https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tebentafusp
[2] https://www.ema.europa.eu/en/medicines/human/EPAR/tebentafusp
[3] https://www.drugpatentwatch.com/p/tebentafusp/